Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) have been assigned an average recommendation of “Buy” ...

Coya Therapeutics (NASDAQ:COYA – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy ...

Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $14.55 which represents a slight increase of $0.42 or 2.97% from the prior close of $14.13. The stock opened at $14.3 and ...

On Friday, Chardan Capital Markets began coverage of Unity Biotechnology Inc (NASDAQ:UBX) shares with a Buy rating and a $6.00 price target, representing significant upside from the current price ...

Eyenovia (EYEN) has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from ...

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (LSE:0YC0) with a Buy recommendation. There are 52 funds or institutions reporting positions in ...

On Friday, Chardan Capital Markets began coverage of Unity Biotechnology Inc (NASDAQ:UBX) shares with a Buy rating and a $6.00 price target, representing significant upside from the current price of ...